Evidence map›Paper›PMID 30564475›Full record

ArticleExperimental hematology & oncology2018

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia.

Yee Yee Yap, Kian Boon Law, Jameela Sathar, Ngee Siang Lau, Ai Sim Goh, Teng Keat Chew, Soo Min Lim, Padmini Menon, Yong Khee Guan, Azlan Bin Husin and 13 more

Abstract read
In one paragraph

Article in Experimental hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Role of JAK2 V617F in Myeloproliferative Neoplasms: From Mutation to Manifestation: A Review.Nigerian medical journal : journal of the Nigeria Medical Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yee Yee YapDepartment of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.ORCID 0000-0002-1515-063X
Kian Boon Law2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
Jameela SatharDepartment of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
Ngee Siang LauDepartment of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
Ai Sim GohDepartment of Haematology, Penang General Hospital, George Town, Penang Malaysia.
Teng Keat ChewDepartment of Haematology, Penang General Hospital, George Town, Penang Malaysia.
Soo Min Lim4Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor Malaysia.
Padmini MenonDepartment of Haematology, Ipoh Hospital, Ipoh, Perak Malaysia.
Yong Khee GuanDepartment of Haematology, Melaka Hospital, Melaka City, Melaka Malaysia.
Azlan Bin Husin7Department of Haematology, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan Malaysia.
Lily Lee Lee Wong8Department of Haematology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah Malaysia.
Lee Ping Chew9Department of Haematology, Sarawak General Hospital, Kuching, Sarawak Malaysia.
Sinari Salleh10Department of Haematology, Hospital Raja Perempuan Zainab II Kota Bahru, Kota Bahru, Kelantan Malaysia.
Kim Yen GohDepartment of Haematology, Ampang Putri Hospital, Ampang, Selangor Malaysia.
Kin Wah LeongDepartment of Haematology, Gleneagles Penang Hospital, George Town, Penang Malaysia.
Sen Mui TanDepartment of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
Tee Chuan OngDepartment of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia.
Su Hong LimDepartment of Haematology, Gleneagles Penang Hospital, George Town, Penang Malaysia.
See Guan Toh4Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor Malaysia.
Xavier Sim Yoon Han4Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor Malaysia.
Syed Carlo Edmund2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia.
Jenq Tzong Tan13Department of Haematology, Taiping Hospital, Taiping, Perak Malaysia.
Kian Meng ChangDepartment of Haematology, Sunway Medical Centre, Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The epidemiology is well described in the western world but not in Asian countries like Malaysia. MATERIALS AND

methodsThis retrospective national registry of MPN was conducted from year 2009 to 2015 in Malaysia.

resultsA total of 1010 patients were registered over a period of 5 years. The mean age was 54 years with male predominance. The ethnic distribution revealed that Chinese had a relatively high weighted incidence proportion (43.2%), followed by Indian (23.8%), Malay (15.8%) and other ethnic groups (17.2%). The types of MPN reported were 40.4% of ET (n = 408), 38.1% of PV (n = 385), 9.2% of PMF (n = 93), 3.1% of hypereosinophilic syndrome (HES) (n = 31) and 7.9% of unclassifiable MPN (MPN-U) (n = 80). Splenomegaly was only palpable clinically in 32.2% of patients. The positive JAK2 V617F mutation was present in 644 patients with 46.6% in PV, 36.0% in ET, 9.0% in PMF, and 7.4% in MPN-U, and had significantly lower haemoglobin (p < 0.001), haematocrit (p < 0.001) and white blood cells (WBC) (p < 0.001) than those with negative mutation. Significant differences in platelet and WBC count were detected in ethnic groups and MPN sub-types. There were more arterial thrombosis events seen in those with JAK2 V617F mutation as compared to venous thrombosis events (23.1% vs 4.4%). The bleeding rate was only 6.6%. Among the risk factors, previous thrombosis, old age (≥ 60 years) and hypertension were significantly correlated to positive JAK2 V617F mutation. The arterial thrombosis event is associated with higher presenting HB, HCT and PLT while the bleeding event is associated with lower presenting HB, HCT but higher PLT. The presence of JAK2 V617F mutation is associated with higher risk of arterial thrombosis.

conclusionChinese ethnicity is associated with higher rates of MPN. The history of thrombosis, age ≥ 60 years and hypertension are risk factors that can be correlated to JAK2 V617F mutation. This study is instrumental for policy makers to ensure preventive strategies can be implemented in future.

Identifiers

PMID30564475
PMCPMC6296047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.